Other Affiliations
and Conflict Disclosure
DirectorAnnual Reviews, BridgeBio Pharma, n-Lorem Foundation, Uncommon Cures, Vesalius TherapeauticsAdvisor toAIF Global, Apricity Health, Aracari Bio, Aurora Therapeutics, BrightEdge Impact Fund, Gondola Bio, Health at Scale, Khora Therapeutics, MIT Proto Ventures, Quantile Health, Ride Therapeutics, Roivant Social Ventures, Rutherford Energy Ventures, Swiss Finance Institute, Thalēs, Think Therapeutics, xCuresCo-FounderQLS TechnologiesCo-Founder and ChairmanQLS AdvisorsPersonal investments inApricity Health, Aracari Bio, BillionToOne, BridgeBio Pharma, Enable Medicine, Inc, Fidelity Select Biotech Fund, Garuda Tx, Instil Bio, Ladder Tx, LS Polaris Innovation Fund, Medallion, MPM Capital Fund, Nautilus Biotech, Nurture Genomics, Peer Collective, Polaris Innovation Fund II, Quantile Health, Royalty Pharma, SURGE Therapeutics, Uncommon Cures, Waypoint Bio
During the most recent six-year period, Lo has received speaking/consulting fees, honoraria, or other forms of compensation from: AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, CME, Enable Medicine, Journal of Investment Management, Lazard, MIT, New Frontier Advisors, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Roivant, SalioGen, Swiss Finance Institute, Think Tx, Vesalius, and WW Norton. In addition, the MIT Laboratory for Financial Engineering (LFE), for which Lo serves as director, has received funding support from the Critical Path Institute, J.P. Morgan Asset & Wealth Management, Schmidt Futures, and Wellcome Leap. [Last updated: 30 July 2025]
